DURAMORPH PF
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DURAMORPH PF (DURAMORPH PF).
Morphine is a full opioid agonist that primarily acts on mu-opioid receptors in the central nervous system to produce analgesia, euphoria, and sedation. It also interacts with kappa and delta receptors. It inhibits ascending pain pathways and alters pain perception and response.
| Metabolism | Primarily hepatic via glucuronidation by UGT2B7 to morphine-3-glucuronide (M3G, inactive) and morphine-6-glucuronide (M6G, active); minor metabolism via CYP2D6 to normorphine. |
| Excretion | Primarily renal (approximately 90% as morphine-3-glucuronide and morphine-6-glucuronide, with 10% as unchanged morphine). Biliary/fecal excretion accounts for less than 10%. |
| Half-life | Terminal elimination half-life of morphine is approximately 2-4 hours in adults. In neonates and elderly, half-life may be prolonged (up to 4.5-6.5 hours). Context: half-life may be extended in renal impairment due to accumulation of active metabolites. |
| Protein binding | 30-35% bound to albumin. |
| Volume of Distribution | 3-5 L/kg (range 1-6 L/kg). Clinical meaning: indicates extensive tissue distribution. |
| Bioavailability | Epidural/Intrathecal: effectively 100% at site of action (systemic bioavailability from epidural absorption is ~30-40% due to first-pass metabolism). Oral: 20-40% (not relevant for DURAMORPH PF). |
| Onset of Action | Epidural: 15-30 minutes; Intrathecal: 15-30 minutes (may be slower with higher doses). |
| Duration of Action | Epidural: 12-24 hours (dose-related); Intrathecal: 12-24 hours (dose-related). Note: duration is longer than systemic administration due to local effect. |
0.8 to 10 mg via epidural injection as a single dose or via continuous epidural infusion at 0.1 to 1 mg/hour. For intrathecal use: 0.2 to 1 mg as a single dose. Intravenous: 2 to 10 mg for analgesia every 2-4 hours as needed.
| Dosage form | INJECTABLE |
| Renal impairment | GFR 50-90 mL/min: no adjustment; GFR 10-50 mL/min: reduce dose by 25-50% and extend dosing interval; GFR <10 mL/min: avoid use or reduce dose by 50% and administer every 6-8 hours with close monitoring. |
| Liver impairment | Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 25-50% and monitor; Child-Pugh Class C: avoid use or reduce dose by 50% and extend dosing interval. |
| Pediatric use | Epidural: 0.03 to 0.05 mg/kg as a single dose, may repeat every 4-6 hours; continuous infusion: 0.002 to 0.008 mg/kg/hour. Intrathecal: 0.01 to 0.02 mg/kg as a single dose. Intravenous: 0.05 to 0.1 mg/kg every 2-4 hours prn. |
| Geriatric use | Reduce initial dose by 25-50% and titrate cautiously due to increased sensitivity and risk of respiratory depression. Use non-PVC tubing and avoid in renal impairment. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for DURAMORPH PF (DURAMORPH PF).
| Breastfeeding | Morphine is excreted into breast milk. M/P ratio is approximately 2.5. Relative infant dose is about 9-10% of maternal weight-adjusted dose. Use with caution; monitor for infant drowsiness, respiratory depression, and constipation. American Academy of Pediatrics considers morphine compatible with breastfeeding, but avoid during labor and delivery due to potential neonatal respiratory depression. |
| Teratogenic Risk | Preservative-free morphine (Duramorph PF) is FDA Pregnancy Category C. First trimester: Limited human data; animal studies show increased risk of neural tube defects and skeletal anomalies at high doses. Second and third trimesters: Chronic use may cause fetal opioid dependence and neonatal opioid withdrawal syndrome (NOWS) after delivery. Not associated with major congenital malformations in human studies, but risk-benefit must be assessed. |
■ FDA Black Box Warning
WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; NEONATAL OPIOID WITHDRAWAL SYNDROID; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS. Ensure proper patient selection, monitoring, and dispensing.
| Serious Effects |
Hypersensitivity to morphine or any component of the formulation; significant respiratory depression; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction, including paralytic ileus; concomitant use of monoamine oxidase inhibitors (MAOIs) or within 14 days of such therapy; respiratory depression in the absence of resuscitative equipment; upper airway obstruction; status asthmaticus; severe chronic obstructive pulmonary disease; cor pulmonale; severe obesity; sleep apnea syndrome; myxedema; delirium tremens; acute alcoholism; increased intracranial pressure; head injury; intracranial lesions; impaired consciousness; coma; convulsive disorders; hypotension; hypovolemia; biliary tract surgery; suspected surgical abdomen; pancreatitis; prostatic hyperplasia; urethral stricture; urinary retention; use in pregnancy when premature delivery is anticipated; during labor when delivery of a premature infant is anticipated; during labor when narcotic antagonist is not available; use in breastfeeding; use in children less than 18 years (except as directed by a physician).
| Precautions |
Loading safety data…
| Fetal Monitoring | Continuous maternal monitoring for respiratory rate, oxygen saturation, sedation level, and pain scores. Fetal monitoring: Non-stress test and biophysical profile in third trimester for chronic use. During labor, fetal heart rate monitoring is essential. For neonates, monitor for signs of withdrawal (NOWS) for at least 48 hours after delivery if mother used chronically. |
| Fertility Effects | Chronic opioid use may cause menstrual irregularities (e.g., anovulation, amenorrhea) due to suppression of gonadotropin-releasing hormone (GnRH). Reversible upon cessation. No known direct effect on spermatogenesis, but sexual dysfunction (e.g., erectile dysfunction, libido changes) may occur in both sexes. Data on fertility impact are limited. |
| Risk of respiratory depression, especially in elderly, cachectic, or debilitated patients; central nervous system depression; serotonin syndrome with serotonergic drugs; adrenal insufficiency; hypotension; seizures; severe hypotension; use in patients with head injury; use in patients with biliary tract disease; use in patients with pancreatic disease; use in patients with renal impairment; use in patients with hepatic impairment; use in patients with respiratory conditions; use in patients with gastrointestinal obstruction; use in patients with prostatic hyperplasia; use in patients with urinary retention; use in patients with hypothyroidism; use in patients with adrenocortical insufficiency; use in patients with toxic psychosis; use in patients with alcoholism; use in patients with delirium tremens; use in patients with kyphoscoliosis; use in patients with severe obesity; use in patients with sleep apnea; use in patients with myxedema; use in patients with chronic obstructive pulmonary disease; use in patients with cor pulmonale; use in patients with respiratory depression; use in patients with acute or severe bronchial asthma; use in patients with paralytic ileus; use in patients with hypersensitivity to morphine; use in patients with gastrointestinal obstruction; weaning from opioids; physical dependence; withdrawal; tolerance; impaired mental or physical abilities; driving; operating machinery; risk of overdose; accidental ingestion; neonatal opioid withdrawal syndrome; concomitant use with alcohol; concomitant use with benzodiazepines; concomitant use with CNS depressants; abuse potential; monitoring; pregnancy; lactation; renal impairment; hepatic impairment; elderly; pediatric; recent intracranial surgery; increased intracranial pressure; impaired consciousness; coma; convulsive disorders; hypotension; hypovolemia; severe pulmonary disease; respiratory depression; sleep-related breathing disorders; drug dependence; misuse; addiction; abuse; diversion; storage and disposal. |